SpringWorks Launches With $103m, Four Pfizer Drugs And A Focus On Underserved Patients
No disease is too small or too large for SpringWorks, which spun out Pfizer with four mid-/late-stage compounds to develop drugs in indications where patients have no good treatment options.
